A systematic review and meta-analysis evaluating the relationship between anti-tumor necrosis factor (anti-TNF) therapy and cardiovascular events in patients with rheumatoid arthritis showed that cardiovascular events were related with a lower risk when anti-TNF medication was used (Barnabe et al., 2011). The gene discussed is TNF; the disease is rheumatoid arthritis.